All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Bookmark this article
Acute myeloid leukemia (AML) is a heterogenous disease associated with a broad continuum of molecular changes. In the past decade, there have been advances in novel treatment strategies including immunotherapies that harness the power of T-cells against AML. These include bispecific and dual antigen receptor-targeting antibodies (targeting CD33, CD123), chimeric antigen receptor (CAR) T-cell therapies, and T-cell immune checkpoint inhibitors (targeting PD-1, PD-L1, CTLA-4).1
During the American Society of Clinical Oncology (ASCO) Meeting 2023, the progress of several ongoing trials evaluating the efficacy and safety of T-cell-based immunotherapies were presented. We are pleased to present a summary of three poster presentations on: the efficacy and safety of vibecotamab by Nicholas Short2; the antileukemic activity and safety of pivekimab sunirine (PVEK) by Naval Daver3; and a first-in-human trial of tocilizumab by Pierre Peterlin.4
Most patients with AML or myelodysplastic neoplasms (MDS) express CD123.2 On normal hematopoietic progenitors, CD123 is expressed at incredibly low levels, making it a potentially effective therapeutic target.
Vibecotamab is a CD3-CD123 bispecific T-cell-engaging antibody (Figure 1) demonstrating clinical activity in patients with relapsed/refractory (R/R) AML. In a phase I study, vibecotamab (dose ≥0.75 µg/kg) demonstrated an overall response rate (ORR) of 26% in patients with ≤25% blasts.
Nicholas Short presented the progress of an open-label, phase II trial of vibecotamab (NCT05285813) in patients with positive measurable residual disease (MRD+) AML, MDS, or chronic myelomonocytic leukemia (CMML) after failure with hypomethylating agents. Patients with either an MRD level of ≥0.1% (by multiparameter flow cytometry), or intermediate/higher-risk MDS, or CMML-1 or CMML-2 are eligible. Enrolled patients are given vibecotamab intravenously (IV) on Days 1 (0.43 µg/kg), 3 (0.75 µg/kg), 5 (1.1 µg/kg), and 8 (1.7 µg/kg) of Cycle 1, followed by a weekly dose of vibecotamab 1.7 µg/kg. The primary endpoint in the MRD+ cohort is the determination of the MRD negativity rate (target 50%), and in the MDS/CMML cohort it is ORR (target 30%) after 4 cycles of vibecotamab.
The trial started in May 2022 and is actively recruiting patients at the MD Anderson Cancer Center. To date, 17 patients have been enrolled, 9 with MRD+ AML and 8 with MDS or CMML. Active recruitment of patients is planned until the end of 2024, with an aim of 20 patients per cohort.
Figure 1. Structure of vibecotamab*
*Adapted from Short.2 Created with BioRender.com.
Long-term survival is inadequate in patients with frontline unfit AML, despite improved outcomes with azacitidine (AZA) and venetoclax (VEN) treatment. Pivekimab sunirine (PVEK) is an antibody–drug conjugate (ADC) that contains an indolinobenzodiazepine pseudodimer payload and a cleavable linker and is a high-affinity CD123 antibody (Figure 2A). According to pre-clinical studies, PVEK in combination with AZA and VEN has demonstrated therapeutic synergy. Clinical evidence also supports continued research into PVEK, AZA, and VEN as a combination therapy. Magrolimab is a monoclonal antibody blocking CD47 (Figure 2B). Magrolimab has shown promise as a monotherapy therapeutic for R/R AML in a phase I study.
Figure 2. A The Structure and mechanism of action of pivekimab sunirine and B the structure and mechanism of action of magrolimab*
*Adapted from Daver.3 Created with BioRender.com.
The trial is comprised of two cohorts:
The primary and key secondary endpoints are listed below:
Cohort C is currently enrolling patients across 29 sites in France, Germany, Italy, Spain, UK, and USA. Cohort E will open for enrollment mid-2023 at the US sites.
Interleukin-6 promotes resistance to chemotherapy and is known to be related to poor prognosis in patients with AML. IL-6 blockade may therefore represent a promising new therapeutic strategy for the management of AML.
Pierre Peterlin presented the early findings from the phase I TOCILAM single-center trial (NCT04547062). This is a first-in-human trial of tocilizumab in combination with standard induction chemotherapy in patients with newly diagnosed AML with a favorable risk, or R/R AML. Three doses of tocilizumab were evaluated: 4, 6, and 8 mg/kg administered on Day 8 of a standard AML induction chemotherapy regimen of idarubicine 8 mg/m2 on Days 1–5 plus cytarabine 100 mg/m2 on Days 1–7. The primary aim of the trial was to determine the maximum tolerated dose of tocilizumab to inform phase II and III studies.
A total of 12 patients were included between December 2020 and 2022 with a median age of 66 years (range, 65–70.5 years) and a median follow-up of 675 days.
The range of ongoing trials evaluating various immune-based therapeutics for the treatment of AML are promising. The TOCILAM study demonstrated that the combination of tocilizumab and standard intensive induction therapy for AML appears to be safe, including higher ORR and the expected biological activity. Further findings from these trials will inform the efficacy and safety data of immune-based therapies in the treatment of AML.
The latest developments on novel agents in the treatment of AML: Updates from #ASCO23 and EHA
Here, we summarize the latest updates on five novel agents: iadademstat, ZN-d5, azenosertib, ziftomenib, and olutasidenib for the treatment of AML were...
The latest on venetoclax combinations in AML from ASH 2021
The BCL-2 inhibitor, venetoclax, has transformed the treatment landscape for acute myeloid leukemia (AML), particularly in cases where patients are considered ineligible for intensive...
Subscribe to get the best content related to AML delivered to your inbox